Evotec AG acquired Evotec Neurosciences in 2005 and is quoted on the Deutsche Börse Stock Exchange. (EVT.DE).
Evotec AG and Roche have announced that they have entered into an agreement for Phase II clinical development of EVT 101 in patients with treatment-resistant depression. The potential value of this transaction exceeds US$300 million.
Evotec AG today announced that a third milestone has been successfully achieved in their collaboration with Boehringer Ingelheim.